Phathom Pharmaceuticals, Inc. PHAT
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a GI/hepatology drug developer. Its lead program, Vonoprazan for eosinophilic esophagitis (EoE), is in Phase 2 for Eosinophilic esophagitis (EoE). Its next catalyst on record is Vonoprazan for eosinophilic esophagitis (EoE): Topline results from Phase 2 trial (12-week blinded treatment portion) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Vonoprazan for eosinophilic esophagitis (EoE) — Topline results from Phase 2 trial (12-week blinded treatment portion) (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VOQUEZNA (vonoprazan) | Erosive GERD | small molecule | Approved |
| VOQUEZNA (vonoprazan) | Non-Erosive GERD - heartburn relief | small molecule | Approved |
| VOQUEZNA DUAL PAK | H. pylori infection | small molecule | Approved |
| VOQUEZNA TRIPLE PAK | H. pylori infection | small molecule | Approved |
| pHalcon-NERD-302 - Vonoprazan as-needed dosing | Non-Erosive GERD (NERD) - PRN regimen | small molecule | Phase 3 |
| Vonoprazan for eosinophilic esophagitis (EoE) | Eosinophilic esophagitis (EoE) | small molecule | Phase 2 |
Recent results and decisions
- Sep 29, 2026started Patient screening initiated in registrational Phase 3 pHalcon-NERD-302 of as-needed vonoprazan in non-erosive GERD (~500 adults, ~80 US sites, 24-week treatment).
Phathom announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive Gastroesophageal Reflux Disease
Filing - Sep 29, 2026started Phathom initiated pHalcon-NERD-302, a registrational Phase 3 study of VOQUEZNA for as-needed use in NERD, with first subject dosed and topline results expected in Q1 2028.
On September 29, 2026, Phathom announced the initiation of pHalcon-NERD-302, a registrational Phase 3 study of VOQUEZNA for as-needed (PRN) use in Non-Erosive Gastroesophageal Reflux Disease (NERD). The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results a
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.